Publications by authors named "Ken F Blount"
Background: Microbiota-based treatments are effective in preventing recurrent Clostridioides difficile infection (rCDI). Fecal microbiota, live-jslm (REBYOTA®; RBL, previously RBX2660) was shown to prevent rCDI in a phase 3, randomized, double-blinded placebo controlled clinical trial (PUNCH™ CD3).
Methods: Stool samples from participants in PUNCH™ CD3 who received a single blinded dose of rectally administered RBL or placebo were sequenced to determine microbial community composition and calculate the Microbiome Health Index for post-antibiotic dysbiosis (MHI-A).
Article Synopsis
- The study focuses on RBX2660, a new investigational treatment for recurrent Clostridioides difficile infection (rCDI), showing promising safety and efficacy compared to standard antibiotics.
- In a Phase 2 trial, RBX2660 achieved a 78.9% treatment success rate, significantly higher than the 30.7% success rate of a historical control group.
- Notably, 91% of patients treated with RBX2660 remained free from CDI for 24 months, suggesting long-lasting effectiveness.
Background: RBX2660 is an investigational microbiota restoration therapy in phase 3 clinical development for preventing recurrent infections (CDIs). In a randomized, double-blinded placebo-controlled phase 2B trial, RBX2660 was effective at preventing CDI recurrence. The current study was performed to characterize the fecal bacterial microbiome before and after treatment among RBX2660- or placebo-treated responders in that trial.
View Article and Find Full Text PDF